Patrick Marcellin

Research interests

Publications

• Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32111-1

• 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

  Journal of Hepatology · 2018 · https://doi.org/10.1016/j.jhep.2017.11.039

• Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening

  Liver International · 2018 · 10.1111/liv.13682

• Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

  ˜The œLancet. Gastroenterology & hepatology · 2016 · 10.1016/s2468-1253(16)30107-8

• Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

  Journal of Hepatology · 2016 · 10.1016/j.jhep.2016.12.022

• Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

  Journal of Hepatology · 2015 · https://doi.org/10.1016/j.jhep.2015.11.012

• Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

  Gastroenterology · 2015 · https://doi.org/10.1053/j.gastro.2015.09.043

• Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402454

• Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

  Journal of Hepatology · 2013 · https://doi.org/10.1016/j.jhep.2013.04.035

• Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61425-1

• A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

  Liver International · 2011 · https://doi.org/10.1111/j.1478-3231.2011.02539.x

• Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1009482

• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1012912

• Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

  Journal of Hepatology · 2011 · https://doi.org/10.1016/j.jhep.2011.06.006

• Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes

  Ultrasound in Medicine & Biology · 2010 · 10.1016/j.ultrasmedbio.2010.07.005

• Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

  Liver International · 2009 · 10.1111/j.1478-3231.2008.01802.x

• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †

  Hepatology · 2008 · 10.1002/hep.22760

• Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0802878

• Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis

  Gastroenterology · 2007 · 10.1053/j.gastro.2007.11.010

• Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases

  Hepatology · 2006 · 10.1002/hep.21420

• Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data

  Gastroenterology · 2006 · 10.1053/j.gastro.2006.03.014

• Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

  Gastroenterology · 2006 · 10.1053/j.gastro.2006.09.020

• Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

  New England Journal of Medicine · 2005 · 10.1056/nejmoa042957

• Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043470

• Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆

  Gastroenterology · 2004 · 10.1053/j.gastro.2004.03.018

• Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

  New England Journal of Medicine · 2004 · 10.1056/nejmoa040431

• Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

  Hepatology · 2004 · 10.1002/hep.20506

• Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

  New England Journal of Medicine · 2003 · 10.1056/nejmoa021812

• Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

  New England Journal of Medicine · 2003 · 10.1056/nejmoa020681

• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  The Lancet · 1998 · https://doi.org/10.1016/s0140-6736(98)07124-4

• Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

  Annals of Internal Medicine · 1997 · 10.7326/0003-4819-127-10-199711150-00003

Current projects

No projects listed.